
The a2z-Omni-Triage software reportedly facilitates adjunctive triage for a number of findings including pneumothorax, coccygeal fracture, bowel perforation and moderate or severe hydronephrosis.
MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new
MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new radiopharmaceutical, 123I-BMIPP (123I-beta-methyl-iodophenylpentadecanoic acid), for detection of cardiac ischemia in the emergency department. The cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, BC.






